Loading
Adding a TIGIT blocker to PD-1/PD-L1 blockade looked good in phase 2 and then failed repeatedly in phase 3.
This caution pairing concerns adding a TIGIT blocker to Immune checkpoint inhibitors against PD-1 or PD-L1, a combination that looked promising in phase 2 and then failed repeatedly in phase 3. SKYSCRAPER-01 (Tiragolumab plus atezolizumab in Non-small-cell lung cancer), SKYSCRAPER-02 in Small-cell lung cancer and other trials were negative, the phase 2 signals did not reproduce, and Roche and others discontinued most TIGIT programmes in 2024-25. The reason for failure is unclear: Fc-effector requirements, patient selection and redundancy with PD-1 are the proposed explanations. The episode is cited in the idea that no accelerated approval should be granted for a combination without proof that each part contributes, and it is linked from the Tiragolumab and TIGIT entries.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares TIGIT, PD-L1, Non-small-cell lung cancer.
Shares TIGIT, Tiragolumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares TIGIT, Tiragolumab.
Shares PD-L1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares TIGIT, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tiragolumab, Immune checkpoint inhibitors.
Shares PD-L1, Small-cell lung cancer, Immune checkpoint inhibitors.